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The goal of this study was to review the origin, clinical relevance and treatment of pulse
pressure (PP). Elevated PP is increasingly being recognized as a risk factor for cardiovascular,
particularly coronary, disease. Pulse pressure is discussed in terms of both Windkessel and
distributive models of the arterial circulation. Pulse pressure arises from the interaction of
cardiac ejection (stroke volume) and the properties of the arterial circulation. An increased
stiffness of the aorta and large arteries leads to an increase in PP through a reduction in arterial
compliance and effects on wave reflection. A number of factors are known to influence arterial
wall behavior and, therefore, PP. In addition to the effects of aging and blood pressure on
arterial wall elasticity, there is some evidence that atherosclerosis, per se, amplifies these
effects. Thus, the relationship between PP and coronary disease may be bidirectional. A
number of dietary and lifestyle interventions have been shown to modify large artery behavior.
These include aerobic exercise training and consumption of n-3 fatty acids. Conversely,
strength training is associated with an increase in arterial stiffness and a higher PP. The effects
of antihypertensive medication have been extensively studied, but many studies are difficult to
interpret because of concomitant change in blood pressure, and to a lesser degree, heart rate.
However a number of studies do suggest direct arterial wall effects, particularly for
angiotensin-converting enzyme inhibitors. A distributed compliance model of the arterial
circulation provides a framework for understanding the causes, effects and potential treatment
of elevations in PP. (J Am Coll Cardiol 2001;37:975–84) © 2001 by the American College
of Cardiology
Pulse pressure (PP) arises as a consequence of the episodic
nature of cardiac contraction and the properties of the
arterial circulation. Thus, while mean arterial pressure is
adequately described by cardiac output and total peripheral
resistance, the origins of PP are more complex. As such, PP
is not explicable by any single, simple model of the circu-
lation. In this review, PP will be discussed in terms of a
synthesis of two complementary model systems, namely the
well-known Windkessel model and one based on the
propagative properties of the arterial circulation.
In its simplest, two-element form, the Windkessel model
describes the circulation in terms of parallel resistance and
capacitance components. The resistance element corre-
sponds to measured peripheral vascular resistance, while the
capacitance element corresponds to the compliance (C) of
the arterial circulation. Compliance is simply a measure of
the capacity of a volume-containing structure, in this case
the arterial system, to accommodate further increases in
volume (D volume/D pressure). While C is widely distrib-
uted throughout the arterial tree, total systemic arterial C is
predominantly determined by the aorta (1) and its major
branches (Fig. 1). Arterial C can be estimated from the
decay in diastolic pressure (2) as well as by the simpler
approach of: C 5 stroke volume (SV)/PP, and studies have
suggested reasonable correspondence between these meth-
ods (3,4). An important feature of the arterial system is that
its C is dependent on initial loading conditions such that it
becomes less at higher pressures. This has important con-
sequences not only in terms of the Windkessel model but
also in terms of the transmission or propagative properties
discussed subsequently. It is apparent from the approxima-
tion C 5 SV/PP that elevation of PP can be secondary to a
rise in SV or a fall in C. The rise in PP (or systolic pressure)
with age in healthy subjects (5) relates to falls in C, whereas
elevation of PP in the young appears to be related to
increases in SV (6).
Analysis solely in terms of the Windkessel model is
limited because this model lumps the arterial tree into the
entities C and resistance, assuming that all pressure changes
occur instantaneously, whereas the circulation serves to
distribute cardiac output through a series of branching
networks. Hence, the Windkessel model is unable to explain
phenomena pertinent to a distributed system, such as wave
reflection and frequency dependence. This is of particular
importance in the understanding of PP. Wave reflection
occurs throughout the arterial tree at each branching of
arteries: a fraction of the forward travelling pulse wave is
reflected back towards the heart, where it summates with
the forward travelling wave. Frequency, distance and vessel
wall-dependent dampening occur of both the forward and
the backward travelling wave. Hence, not surprisingly,
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reflected waves returning to the heart originate predomi-
nantly at the major branches of the aorta and its terminal
tapering (7) (Fig. 1). This is due to the proximity of these
points to the heart, resulting in reduced dampening and in
the amount of reflection, which, among other determinants,
relates to the amount of change in vessel diameter at a
branching site.
The correspondence of forward and backward waves will
also be determined by their respective timing at any given
point of measurement. Augmentation of central systolic
pressure refers to the superposition of a visible reflected
wave onto the forward travelling wave generated by left
ventricular (LV) ejection. This superposition is often no-
ticeable as an inflection on the aortic pressure trace, and it
may lead to an increase in systolic pressure (and, hence, PP)
over and above that generated by LV ejection alone.
Peripherally, PP amplification refers to the phenomenon
wherein the PP measured at a peripheral artery is amplified
vis-a-vis that present in the proximal aorta. Although this
amplification is lower for the brachial than it is for the
femoral artery and lower in older as compared with younger
age groups, it is important to note that peripheral estimates
of PP are not identical to measured central PP.
Pulse pressure, thus, depends on LV ejection and the
properties of the arterial wall, which determine both the C
and the transmission characteristics of the arterial system.
While the advantage of the two-element Windkessel model
is its simplicity, including the ability to describe the arterial
system through simple numbers, that is, C and resistance, it
fails to characterize other important determinants. Consid-
ering the arterial system as comprising a distributed C
overcomes these limitations to a large extent. However, as
both relate to the same fundamental, that is, the properties
of the arterial wall, both approaches may be appropriate
depending on circumstances.
PP and anthropometric factors. EFFECTS OF AGE, GEN-
DER, HEIGHT, HEART RATE. Aging is associated with a loss
of elasticity in the aorta and major arterial conduits. The
increase in large artery, particularly aortic, stiffness resulting
from fragmentation and disruption of elastic lamellae and
alteration in the collagen to elastin ratio is of profound
importance to the genesis of increased PP with age (5,8,9).
The consequences of this increase in stiffness are important
in both Windkessel and propagative models of the circula-
tion by leading to both reduced arterial C and increased
pulse wave velocity (PWV). Reduced C will increase PP due
to a reduced “buffering” capacity available from the arterial
wall while the concomitant increase in PWV will increase
systolic pressure augmentation, as discussed in more detail
in the following text.
Loss of arterial elasticity, in the absence of compensatory
dilation, will both reduce arterial C and increase the speed
of wave transmission due to the dependence of the latter on
vessel wall properties as given in the Bramwell-Hill and
Moens-Korteweg equations (10–12). The latter effect will
lead to earlier return of the reflected pressure wave. Hence,
the reflected wave superposes earlier during systole, result-
ing in increased systolic pressure augmentation, thereby also
increasing central PP. Changes in reflection coefficient (i.e.,
the proportion of forward to backward travelling wave) and
the site of major reflection could also contribute to altered
magnitude and timing of wave reflection and, therefore,
central pressure augmentation. Animal data suggest that
age-related increases in atheroma at branch sites could
induce changes by these mechanisms, but no evidence is
available to support such a proposal in humans (13). The
time taken for return of the reflected pressure wave will also
depend on distance to principal reflection sites and, hence,
on body height. There is ample evidence for a relation
between central pressure augmentation and height (14–16).
Such a relation could be expected to produce male-female
differences, and, indeed, augmentation index is greater in
women than it is in men (14–16). Whether there are
body-size independent differences is less certain. The cen-
tral coincidence of forward and backward waves will also
depend on the timing of ventricular ejection. Due to the
proportionality between ejection time and cardiac cycle
duration (17,18), the peak of the forward travelling wave
will be relatively delayed at slower heart rates. Thus, even
with a fixed reflection site and speed of wave transmission,
there will be an altered relationship between forward and
backward waves. Central pressure augmentation and, thus,
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
C 5 compliance
DBP 5 diastolic blood pressure
LV 5 left ventricle or left ventricular
PP 5 pulse pressure
PWV 5 pulse wave velocity
SBP 5 systolic blood pressure
SV 5 stroke volume
Figure 1. Pulse pressure (PP) arises from the interaction between stroke
volume (SV) and the characteristics of the arterial circulation that deter-
mine compliance (C) and wave reflection. As discussed in the text, wave
reflection occurs at multiple sites but is shown in the diagram as a single site
for the sake of simplicity. Cardiac output and peripheral vascular resistance
(PVR) determine mean arterial pressure (MAP).
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central PP will, therefore, be amplified at lower heart rates
(14). The somewhat faster heart rate found in women will,
therefore, to an extent, counteract the effects of shorter
stature.
A number of nonpharmacological (19–23) as well as
pharmacological interventions (discussed subsequently)
have been shown to result in short-term modifications to
large artery properties. These appear to be in excess of the
effects attributable to change in mean pressure and which
operate through the nonlinear characteristics of large artery
wall behavior, leading to reduced stiffness at lower pressures.
The most plausible explanations for ‘direct’ arterial wall
effects appear to be change in smooth muscle tone leading to
alterations in the proportion of load borne by elastic vis a vis
nonelastic tissues (24) and changes in the vasa vasorum,
which have been shown to affect large artery properties
(25,26). Short-term change in functional cross-links could
also contribute to this.
EFFECTS OF CHOLESTEROL, DIABETES, HYPERTENSION,
HOMOCYSTEINE. A number of pathophysiological states
have also been shown to affect large artery properties.
Interestingly, elevated cholesterol levels, in the absence of
overt atheroma, appear to be associated with reduced, rather
than enhanced, aortic stiffness. In a study of asymptomatic
subjects with marked hypercholesterolemia, aortic stiffness
showed a less steep increase with age than was the case for
control subjects (27). Similarly, very young subjects with
familial hypercholesterolemia showed more compliant large
arteries (28), whereas somewhat older subjects with familial
hypercholesterolemia showed reduced large artery C in one
study (29) but not another (30). The latter study did not
find any relation between standard lipid variables and aortic
C, which was, however, reduced with increasing levels of
oxidized low-density lipoprotein. Asymptomatic 35-year-
old men showed a negative correlation between aortic
stiffness and low-density lipoprotein cholesterol (31). A
similar situation has been demonstrated in diabetes where
very early investigation of young subjects with type I
diabetes were found to have increased arterial C, whereas
older subjects with type II diabetes (likely to have macro-
vascular disease) had less distensible large arteries (32).
Diabetic subjects appear to be particularly susceptible to the
effects of a high salt diet in reducing C (33) but are
responsive to fish oils (20). In addition to diabetes, hyper-
tension has also been found to reduce brachial artery
distensibility (34). Salt sensitive hypertensive subjects have
lower large artery C than those who are salt resistant (35).
Although elevated plasma levels of homocysteine have been
related to systolic hypertension (36), there appears to be
little effect on the stiffness of carotid or femoral arteries
(37,38).
PP amplification. Pulse pressure measured at the brachial
artery will also be subject to the effects of alteration in large
artery properties. Transmission of arterial pressure to the
periphery is accompanied by PP amplification. Mechanisms
proposed to account for this include reflection from distal
sites (39) as well as nonlinearity in the forward travelling
wave from the heart (40). This leads to central-peripheral
PP differences that diminish with age due to the effect of
arterial stiffening in producing central systolic pressure
augmentation (41). The relationship between brachial PP
and height suggests that the phenomenon of peripheral
pressure amplification is also affected by transmission length
(42). Systolic pressure and PP measured at the brachial
artery rise with age. Data from the U.S. suggest a greater
increase in brachial PP with age in women compared with
that in men, but this is not evident in all populations (43).
The phenomenon of PP amplification may have impor-
tant consequences when considering clinical end point
studies (discussed in the following text). The overwhelming
majority of these studies have measured pressure at the
brachial artery, whereas important pathophysiological con-
sequences of change in PP, such as cardiac hypertrophy and
function and coronary perfusion, are related to central
pressure. The importance of the disparity between central
and peripheral PP is somewhat lessened by its diminution
with age, but it is nonetheless important not to ignore its
potential impact.
Summary. Arterial (primarily aortic) stiffening, such as
occurs with age, increases PP by reducing C and increasing
PWV. An increase in PWV leads to earlier return of the
reflected wave with systolic pressure augmentation. A rise in
mean blood pressure will operate similarly to increase PP
due to the nonlinear stress-strain behavior of the arterial
wall, leading to increased stiffness at higher distending
pressures. Changes in the coincidence of forward and
backward travelling waves underlie the effects of height and
heart rate, with short stature and slow heart rate both
favoring systolic pressure augmentation and increased PP.
Comparison of PP between populations or study groups
need consideration of these arthropometric factors including
the effects of PP amplification at peripheral sites.
Surrogate and end point clinical studies. A number of
studies have investigated relationships between PP and
surrogate end points such as vascular structure and LV
hypertrophy. Measures of PP have included conventional
brachial sphygmomanometry, ambulatory monitoring, in-
cluding intra-arterial pressure recording and site specific
measures of PP, including those obtained noninvasively by
tonometry. To date, little information is available to relate
central pressures to clinical end points. An important
consideration in interpreting studies on PP and clinical and
surrogate end points is the extent to which the effects of PP
can be shown to be independent of the effects of other blood
pressure terms, particularly mean pressure.
Surrogate end points. Increases in clinic and ambulatory
PPs were the only significant predictors of wall thickness/
lumen ratio in subcutaneous arterioles harvested from skin
buttock biopsies of normotensive and hypertensive subjects
(44). Both PP terms remained independently significant in
the presence of age and other clinic blood pressure terms. In
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a study of hypertensive subjects, those with PP $60 mm Hg
had higher values for LV mass than those with PP
#60 mm Hg, despite similar mean pressures (45). In a
cross-sectional study of normotensive and untreated hyper-
tensive subjects, carotid intima-media thickness was related
to carotid, but not to radial, PP or to mean pressure (46). In
a nine-month study of patients with essential hypertension
treated with either an enalapril- or celiprolol-based treat-
ment regimen, the change in carotid intima-media thick-
ness was related to the fall in central pulse but not mean
pressure (47). In a study of patients undergoing 24-h
intraarterial blood pressure monitoring on the basis of
elevated clinic pressures, both carotid intima-media thick-
ness and LV mass index were related to baseline PP after an
average follow-up of more than nine years (48). In this
study, relations were evident between these end points and
both intraarterial brachial systolic blood pressure (SBP) and
PP, but not diastolic blood pressure (DBP) (48). In post-
menopausal women, carotid intima-media thickness has
been related to the elevation in PP produced by mental
stress (49). In an eight-year follow-up study of women
traversing menopause, baseline SBP, but not DBP, was
predictive of increases in both coronary and aortic calcium
scores (50). Regression of LV hypertrophy by pharmaco-
logical treatment in spontaneously hypertensive rats was
dependent on changes in pulsatile load, despite similar
effects on mean pressure (51).
Clinical events. Despite finding a positive association be-
tween PP and electrocardiogram abnormalities in a cross-
sectional study, a Chicago Heart Association and Health
Department study failed to find a relation between PP and
subsequent mortality (52–54). However, a number of other
studies have found positive associations between PP and a
range of subsequent cardiovascular clinical end points. In
the Framingham Study, while SBP, DBP and PP were all
positively related to outcome when entered individually,
when entered in combination the association was negative
for DBP, with PP being at least as good a predictor as the
other terms for the middle-aged and elderly (55,56). In the
Boston Veteran’s Administration Study of healthy male
volunteers aged 21 to 80 years at enrollment, cardiovascular
death was related to baseline SBP in younger (,60 years)
subjects, whereas in older (.59 years) subjects PP appeared
to be a more accurate predictor of death than SBP or DBP
(57). In a 10-year follow-up of .13,000 Dutch women aged
$50 at baseline who were participating in a breast screening
program, baseline SBP was positively and monotonically
related to stroke and total mortality (58). However, the
relation between SBP and subsequent coronary events and
cardiovascular mortality was J shaped, with an apparent
increase at lower SBP levels (58). In a noninvasive 24-h
ambulatory study of initially untreated subjects with essen-
tial hypertension, both baseline SBP and PP were related to
cardiovascular events and mortality over a mean follow-up
of 3.8 years with a stronger relationship for ambulatory
compared with clinic pressures (59). In the Medical Re-
search Council (MRC) mild hypertension trial, combined
fatal and nonfatal myocardial infarcts were related to base-
line PP (and SBP), whereas mean arterial pressure was a
better predictor of stroke (60). In a study of .19,000 men
initially aged 40 to 69 years, brachial PP was a predictor of
cardiovascular mortality over a mean follow-up of 19.5
years. Importantly, this association was evident at both low
and high mean pressure (61). In the Studies Of Left
Ventricular Dysfunction (SOLVD) study of patients with
impaired LV function in which more than 70% had had a
previous myocardial infarction, baseline brachial PP was a
predictor of total and cardiovascular mortality and remained
so in multivariate analysis even after adjustment for mean
pressure and a range of other covariates (62). In contrast,
with such adjustment, baseline mean pressure showed a
significant inverse relation with total and cardiovascular
mortality. In the Systolic Hypertension in the Elderly
Program (SHEP) of elderly subjects with isolated systolic
hypertension, both stroke and total mortality were related to
increased PP at baseline independent of mean pressure (63).
In the East Boston senior health project, baseline brachial
PP was an independent predictor of congestive heart failure
in male and female subjects .65 years who were free of
congestive failure at baseline and who were followed for an
average of 3.8 years (64).
Summary. Pulse pressure has been related to a number of
surrogate end points such as LV hypertrophy, and, in addition,
baseline PP has been found to be predictive of subsequent
cardiovascular, particularly coronary, events. Of particular
importance is the finding in several studies that PP is as
good or better a predictor than other blood pressure terms.
Intervention studies. Intervention studies have not been
specifically designed to address the question of PP. How-
ever, there have been studies with isolated systolic hyper-
tension as the entry criterion. Since such studies have
required normal diastolic pressures, they have inevitably
included subjects with elevated PPs. In the Systolic Hyper-
tension in Europe study with the calcium channel blocker
nitrendipine, there was a significant reduction of 41% in
stroke and a reduction of 26% in combined coronary events
(65). In the SHEP trial, there was a reduction of 36% in
stroke and 27% in combined coronary events (66). The
Systolic Hypertension in China study of isolated systolic
hypertension in the Chinese community also reported
significant reductions in both stroke and combined coronary
and sudden deaths (67–69). A recent meta-analysis found
that active treatment in patients aged $60 with SBP
$160 mm Hg and DBP #95 mm Hg reduced stroke by
30%, coronary events by 23% and total mortality by 18%
(70).
Bidirectionality-elevated PP as cause and effect. While
there is substantial evidence linking an elevated PP to
adverse cardiovascular outcomes, there has been little study
of possible mechanisms linking PP to cardiovascular pathol-
ogy. Pulse pressure elevation was shown to induce endothe-
lial dysfunction as assessed by acetylcholine reactivity (71) in
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small vessels, and endothelial dysfunction is a possible
antecedent of atherosclerosis. As discussed, PP has also
been related to LV hypertrophy. A possible additional
explanation for the relationship between PP and cardiovas-
cular end points is provided by the concept of bidirection-
ality—that is, an elevated PP is both a cause and a
consequence of atherosclerosis (Fig. 2). Thus, if atheroma
were widely distributed throughout the arterial system at an
early, presymptomatic stage and if the presence of such
atheroma led to increased large artery stiffness, this could
result in a statistical association between baseline PP and
future clinical events. Such a proposition requires evidence
that atherosclerosis is indeed associated with large artery
stiffness, as discussed in detail in the following text. Al-
though such evidence cannot prove that aortic stiffness
would have been increased at an earlier stage in the disease
process, a recent outcome study found that aortic stiffness at
baseline, as measured by PWV, was predictive of both
all-cause and cardiovascular mortality, even with adjustment
for other risk factors, indicating a prognostic role for aortic
properties per se (72).
Atherosclerosis and large artery stiffness. It is recognized
that coronary atheroma is often accompanied, even at an
early phase, by disease in other large vessels, particularly the
thoracic and abdominal aorta (73,74). Indeed, one explana-
tion for the observed relationship between elevated inflam-
matory risk markers such as C-reactive protein and future
coronary events (75) can be that such elevation is a marker
of a widespread atheromatous process. The aorta and major
arteries are known to stiffen with age, but several studies
have found that the presence of widespread atheroma
amplifies this effect. Thus, measurements of the stiffness of
the aorta in the proximal ascending aorta, the aortic arch
and the abdominal aorta have all been shown to be elevated
in patients with coronary disease (27,76–78). Similarly,
arterial C, largely contained within the aorta, has been
shown to be significantly lower in such patients (79).
Negative studies have also been reported, but these have not
identified subjects on the basis of presentation with clinical
coronary disease. In a study of asymptomatic men, there was
no relationship between aortic C, estimated from PWV,
and coronary calcification (80), determined by ultra-fast
computed tomography. Compliance adjusted for mean ar-
terial pressure did, however, correlate negatively with the
number of extra-coronary disease sites, but only before
adjustment for the effects of age. As discussed, it has
become clear in recent years that coronary events are more
closely predicted by systolic and PP, both consequences of
increased arterial stiffness, than by diastolic pressure (61,81).
In a recent study, we were able to show that the elevation in
PP in subjects with coronary disease was closely associated
with an increase in echocardiographically measured aortic
stiffness (77).
The demonstration of an association between aortic
properties and atherosclerotic, including coronary, disease
cannot, per se, be informative about the direction of
causality. Thus, it is possible that a rise in PP due to
degenerative changes (8) is an initiating event in the
subsequent development of atherosclerosis. Even if this
were so, it does not preclude the operation of a “positive
feedback” as shown in Figure 2. The damaging effect of PP
may itself operate through inducing further, repetitive
arterial wall damage. Changes in arterial stiffness can
certainly appear early in the development of experimental
atherosclerosis (82) and be exacerbated by mechanical dam-
age (83).
Coronary perfusion. An additional phenomenon, which
may also restrict the potential benefit from blood pressure
reduction, relates to impairment of coronary perfusion.
Experimental studies have established that the presence of a
stiffened proximal circulation, achieved by bandaging the
aorta in vivo, or the use of a stiffened bypass circulation is
associated with reduced coronary perfusion, and this is
particularly noticeable subendocardially and in the presence
of a coronary artery stenosis (84,85). This situation would
likely be exacerbated by a treatment-induced reduction in
mean pressure. A potential adverse effect of blood pressure
reduction has previously been aired in man in relation to the
existence of a J-shaped curve relating blood pressure treat-
ment to coronary outcome (86–88). In the recently pub-
lished Hypertension Optimal Treatment study, there was a
trend to increasing cardiovascular mortality for subjects with
diastolic pressure reduced to ,80 mm Hg, whereas stroke
(all) showed a further progressive decline (89).
Summary. Some, but not all evidence, indicates that ath-
erosclerosis, per se, is associated with an increase in aortic
stiffness (and a reduced C) over and above that due to aging.
Widened PP may exacerbate myocardial ischemia as a result
of increased afterload and reduced coronary perfusion.
PP as a therapeutic target. Despite the impressive epide-
miological associations between PP and cardiovascular end
points and outcomes, it is currently premature to identify
reduction of PP, per se, as a therapeutic goal. As indicated
in the introduction, PP will fall with any reduction in mean
pressure. A more targeted approach to lowering PP, if
eventually indicated, will come from an increase in arterial
Figure 2. Schematic diagram illustrating the concept of bidirectionality in
the relationship between pulse pressure (PP) and atherosclerosis. Elevated
PP promotes vascular damage, an antecedent to atherosclerosis, which
results in large-vessel stiffening and increased wave reflection, thus, further
amplifying PP. While it is not clear which is the incipient event in this
cycle, it is clear that, once initiated, a vicious cycle promoting disease
progression ensues.
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C. In addition to pharmacological agents, increases in
arterial C can be achieved by a variety of nonpharmacologi-
cal means, such as exercise training (19,90) and dietary
manipulations, particularly including n-3 fatty acids (20,22),
estrogen compounds (21) and reduced salt intake (91).
Hormone replacement therapy in postmenopausal women
has been shown to increase arterial C and to lower central
(aortic) PP (92–94). All these effects appeared in excess of
those predicted from the change in mean pressure. In
contrast with the effects of aerobic training, muscle strength
training was associated with increased arterial stiffness and
increased PP (95).
A number of studies have been carried out to compare the
effects of different agents and classes on arterial properties
that are relevant to the issue of PP. When considering such
studies, a number of additional factors need to be consid-
ered. Thus, the nonlinearity of arterial elasticity means that
a reduction of distending pressure will, parri passu, lead to
a reduction in arterial stiffness. There may also be heart rate
effects on arterial properties (96,97). An additional consid-
eration in many studies is the location and class of artery
under investigation. Thus, many studies have only examined
muscular or peripheral arteries, such as the brachial artery,
which may not be representative of more proximal vessels.
The pathophysiological consequences of change in PP largely
relate to change in central, rather than peripheral, pressures.
Angiotensin-converting enzyme inhibitors. In a placebo-
controlled crossover study of the acute effects of the
angiotensin-converting enzyme (ACE) inhibitor, quinapril,
in patients with essential hypertension, there were increases
in carotid artery distensibility and aortic C (determined by
PWV). Whereas all the effects on the carotid artery could be
attributed to effects secondary to blood pressure reduction,
the effects on aortic distensibility appeared to be a combi-
nation of direct and blood pressure-dependent effects (98).
Pulse pressure was reduced by a similar amount at both
carotid and brachial sites. In a catheter laboratory study with
intravenous captopril, large artery C was lower in hyperten-
sive, compared with normotensive, subjects and was in-
creased by captopril but not to the values found in normo-
tensive subjects (99). In another acute study, neither
intravenous dihydralazine nor perindoprilat significantly
altered carotid-femoral PWV in patients with mild-
moderate hypertension (100). However, while there was a
strong correlation between change in blood pressure and
PWV in the dihydralazine group, there was no such
correlation with perindoprilat, which was interpreted as
implying a direct arterial effect of the ACE inhibitor.
Ramipril reduced aortic PWV in hypertensive subjects
treated for 42 days. Although blood pressures were lowered,
there was no relationship between change in PWV and
change in diastolic or mean blood pressure, suggesting a
blood pressure independent effect (101). Three months
treatment with perindopril increased brachial artery C in
comparison with placebo in a single-blind study in hyper-
tensive subjects without changing tangential tension, again
suggesting a direct effect on arterial wall properties (102). In
a single-blind, crossover comparison of eight weeks treat-
ment with the ACE inhibitor lisinopril or the calcium
channel blocker nifedipine in elderly subjects with essential
hypertension, aortic PWV was reduced significantly more
by lisinopril, despite there being no difference in their effect
on mean arterial pressure, suggesting an arterial wall affect
of ACE inhibitors (103).
Calcium channel blockers. In a double-blind, crossover
comparison of 12 weeks treatment with the calcium channel
blocker felodipine or the diuretic hydrochlorothiazide in
subjects with mild-to-moderate hypertension, there were
more pronounced falls in PWV at carotid-femoral as well as
peripheral sites with felodipine (104). However, felodipine
was also associated with greater blood pressure reduction
(104). The finding of brachial artery dilation with felodip-
ine, but not hydrochlorothiazide, however, indicated direct
arterial wall effects of the calcium channel blocker. Periph-
eral C, determined by brachial-radial PWV measurement,
was improved by the calcium channel blocker nicardipine
but not by the beta-adrenoceptor antagonist atenolol in
hypertensive subjects treated for eight months (105). In a
parallel group comparison of hydrochlorothiazide with ni-
trendipine in subjects with mild to moderate hypertension
treated for two months, there were no significant differences
in effects on muscular radial artery C (106). Effects of
nitrendipine (as well as perindopril) in hypertensive subjects
appeared to be determined by angiotensin II receptor I
genotype. Thus, whereas PWV change with perindopril was
more marked in those with a C allele, only those with the
AA allele showed a PWV effect with nitrendipine (107).
Alpha- and beta-adrenoceptor antagonists. In an acute
invasive study in which aortic PWV was inferred from the
first minimum of the impedance modulus, PWV was
unaffected by beta-adrenoceptor blockade but was reduced
by combined alpha- and beta-blockade (108). As discussed,
in a comparative study with nicardipine, atenolol did not
affect peripheral PWV in long-term treatment of hyperten-
sive subjects (105). However, in another study, atenolol
reduced aortic PWV as well as blood pressure (109). In
other studies of beta-adrenoceptor antagonists, whereas six
weeks treatment with metoprolol had no significant effect
on brachial-radial or carotid-femoral PWV in hypertensive
subjects (110), four weeks treatment with bisoprolol reduced
both peripheral and central PWV (111). In an eight week
study in patients with essential hypertension comparing
atenolol with the ACE inhibitor fosinopril, augmentation
index, a marker of large artery properties, was reduced more
by fosinopril than it was by the beta-adrenergic blocking
agent (112). However, no adjustment was made for the
lower heart rate in the atenolol-treated subjects and, as
discussed, augmentation index is known to be increased at
slower heart rates.
Diuretics and nitrates. Acute administration of isosorbide
dinitrate to untreated hypertensive subjects increased C at
brachial, carotid and femoral sites when measured with an
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echocardiography tracking device (113). Nitrate therapy
also produced a fall in blood pressure and in wave reflection
as assessed by central pressure augmentation (113). A single
oral dose of nicorandil reduced blood pressure and periph-
eral PWV in hypertensive subjects (114). In a comparison of
a potassium-losing with a potassium-sparing diuretic in
hypertensive subjects treated for six weeks, both lowered
blood pressure from baseline but did not significantly affect
PWV (115).
Despite a considerable body of work, there is still uncer-
tainty over the direct effects of a number of antihypertensive
agents on large artery properties. However, a number of
studies have suggested that ACE inhibitors and, to a lesser
extent, calcium channel blockers do exert direct arterial wall
effects and induce changes not solely due to the passive
effects of blood pressure lowering. The newer techniques of
tonometry and wall tracking do allow examination of
arterial wall properties at different pressures, but these
studies are limited to accessible (peripheral) arteries,
whereas the major contributor to systemic arterial C and,
therefore, PP is the aorta, which cannot be studied by these
techniques. A promising new approach in assessing central
pressure changes is the use of transfer functions to estimate
central arterial waveforms and pressures from recordings at
peripheral sites (116).
Summary. Since PP elevation is predominantly a conse-
quence of increased large artery stiffness, a targeted effect on
PP in excess of that attributable to a reduction in mean
pressure would be expected from treatments and interven-
tions that affect large arteries. An effect on large artery
properties has been demonstrated for a number of nonphar-
macological interventions, including aerobic exercise train-
ing and dietary consumption of n-3 fatty acids. Studies of
the effects of pharmacological therapy have been somewhat
confounded by change in mean pressure (and heart rate),
but there is evidence for specific large artery effects, most
consistently for ACE inhibitors.
Conclusions. Determinants of PP can be adequately dis-
cussed in terms of a model of distributed C, with arterial
wall properties determining both C and transmission char-
acteristics. There is now extensive epidemiological evidence
for a positive relationship between PP and future cardiovas-
cular events, and some evidence that PP modification, per
se, affects cardiovascular end points. However, more evi-
dence is required before it can be firmly concluded that
reduction in PP should be a specific therapeutic target. The
acquisition of such evidence would be helped by therapies
that specifically target PP, rather than mean pressure.
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